Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.
Fifty-six patients with disseminated malignant melanoma were randomly allocated to two treatment groups. The first group C received combination chemotherapy consisting of DTIC and ICRF 159. The second group (C+I) received the same chemotherapy but were also immunized with 2 X 10(7) irradiated allogeneic melanoma cells mixed with 50 mug of percutaneous BCG. The survival rates in both treatment groups C and (C+I) were not significantly different, and only minor enhancement of the chemotherapy was found in the (C+I) group. A similar pattern of tissue response was observed in both groups: lymph node, skin and, to some extent liver metastases, respond better than other sites.
D000951:Antigens, Neoplasm; D001500:BCG Vaccine / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011929:Razoxane / Q000627:therapeutic use*; D014226:Triazenes / Q000627:therapeutic use*
D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D010879:Piperazines; D014226:Triazenes; D011929:Razoxane; D003606:Dacarbazine